Matches in SemOpenAlex for { <https://semopenalex.org/work/W1857358013> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W1857358013 endingPage "1540" @default.
- W1857358013 startingPage "1535" @default.
- W1857358013 abstract "PURPOSE The aim of this study was to evaluate the efficacy and toxicity of gemcitabine at higher doses than had been used previously in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Eighty-four patients (65 men, 19 women; age range, 35 to 75 years; mean age, 59 years) with locally advanced or metastatic pathologically documented NSCLC were enrolled. Patients had bidimensionally measurable disease, as defined by computed tomographic (CT) scan or chest x-ray. A total of 28.6% had previously been surgically treated, while 9.5% had received radiotherapy. Fifty-three patients commenced at a dose of 1,000 mg/m2, and 31 at a dose of 1,250 mg/m2. Patients were to receive two dose escalations of 25%, provided that overall toxicity was no worse than World Health Organization (WHO) grade 1 or WHO grade 0 for platelets. Responding patients were reviewed and validated by a blinded oncology review board (ORB) of experts not involved with the study. Of the original 84 patients enrolled, 76 were assessable. RESULTS The overall response rate was 20% (95% confidence interval [CI], 11.6% to 30.8%). There were two complete responses (3%) and 13 partial responses (17%). Hematologic toxicity was negligible. WHO grade 3 WBC toxicity occurred in 0.9% of doses and WHO grade 4 in 0.1%. WHO grade 3 and 4 thrombocytopenia occurred in 0.1% and 0.1% of all doses, respectively. Nonhematologic toxicity was minor and easily controlled. Common side effects included peripheral edema, asthenia, and transient malaise. CONCLUSION The single-agent efficacy of gemcitabine is equivalent to other agents commonly used to treat NSCLC. Gemcitabine has an unusually mild side effect profile for such an active agent. The nausea and vomiting experienced with gemcitabine are mild and generally well controlled with standard antiemetics; 5-HT3 receptor antagonists are typically not required. The use of gemcitabine does not cause significant alopecia, and hematologic toxicity is modest and unlikely to require hospitalization. Gemcitabine may have a role as monotherapy in patients with inoperable NSCLC." @default.
- W1857358013 created "2016-06-24" @default.
- W1857358013 creator A5010872796 @default.
- W1857358013 creator A5026230148 @default.
- W1857358013 creator A5035654267 @default.
- W1857358013 creator A5052633299 @default.
- W1857358013 creator A5072392269 @default.
- W1857358013 creator A5074357351 @default.
- W1857358013 date "1994-08-01" @default.
- W1857358013 modified "2023-10-03" @default.
- W1857358013 title "Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study." @default.
- W1857358013 cites W1858072261 @default.
- W1857358013 cites W1890647543 @default.
- W1857358013 cites W1971807790 @default.
- W1857358013 cites W2056069559 @default.
- W1857358013 cites W2084562398 @default.
- W1857358013 cites W2120242888 @default.
- W1857358013 cites W2130164889 @default.
- W1857358013 cites W2154737435 @default.
- W1857358013 cites W2168555194 @default.
- W1857358013 cites W3142144633 @default.
- W1857358013 cites W414869133 @default.
- W1857358013 doi "https://doi.org/10.1200/jco.1994.12.8.1535" @default.
- W1857358013 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8040664" @default.
- W1857358013 hasPublicationYear "1994" @default.
- W1857358013 type Work @default.
- W1857358013 sameAs 1857358013 @default.
- W1857358013 citedByCount "349" @default.
- W1857358013 countsByYear W18573580132012 @default.
- W1857358013 countsByYear W18573580132013 @default.
- W1857358013 countsByYear W18573580132014 @default.
- W1857358013 countsByYear W18573580132015 @default.
- W1857358013 countsByYear W18573580132016 @default.
- W1857358013 countsByYear W18573580132017 @default.
- W1857358013 countsByYear W18573580132018 @default.
- W1857358013 countsByYear W18573580132019 @default.
- W1857358013 countsByYear W18573580132020 @default.
- W1857358013 countsByYear W18573580132021 @default.
- W1857358013 countsByYear W18573580132022 @default.
- W1857358013 countsByYear W18573580132023 @default.
- W1857358013 crossrefType "journal-article" @default.
- W1857358013 hasAuthorship W1857358013A5010872796 @default.
- W1857358013 hasAuthorship W1857358013A5026230148 @default.
- W1857358013 hasAuthorship W1857358013A5035654267 @default.
- W1857358013 hasAuthorship W1857358013A5052633299 @default.
- W1857358013 hasAuthorship W1857358013A5072392269 @default.
- W1857358013 hasAuthorship W1857358013A5074357351 @default.
- W1857358013 hasConcept C121608353 @default.
- W1857358013 hasConcept C126322002 @default.
- W1857358013 hasConcept C141071460 @default.
- W1857358013 hasConcept C197934379 @default.
- W1857358013 hasConcept C2776256026 @default.
- W1857358013 hasConcept C2777482430 @default.
- W1857358013 hasConcept C2780258809 @default.
- W1857358013 hasConcept C29730261 @default.
- W1857358013 hasConcept C31760486 @default.
- W1857358013 hasConcept C71924100 @default.
- W1857358013 hasConcept C90924648 @default.
- W1857358013 hasConceptScore W1857358013C121608353 @default.
- W1857358013 hasConceptScore W1857358013C126322002 @default.
- W1857358013 hasConceptScore W1857358013C141071460 @default.
- W1857358013 hasConceptScore W1857358013C197934379 @default.
- W1857358013 hasConceptScore W1857358013C2776256026 @default.
- W1857358013 hasConceptScore W1857358013C2777482430 @default.
- W1857358013 hasConceptScore W1857358013C2780258809 @default.
- W1857358013 hasConceptScore W1857358013C29730261 @default.
- W1857358013 hasConceptScore W1857358013C31760486 @default.
- W1857358013 hasConceptScore W1857358013C71924100 @default.
- W1857358013 hasConceptScore W1857358013C90924648 @default.
- W1857358013 hasIssue "8" @default.
- W1857358013 hasLocation W18573580131 @default.
- W1857358013 hasLocation W18573580132 @default.
- W1857358013 hasOpenAccess W1857358013 @default.
- W1857358013 hasPrimaryLocation W18573580131 @default.
- W1857358013 hasRelatedWork W1823675119 @default.
- W1857358013 hasRelatedWork W2003938723 @default.
- W1857358013 hasRelatedWork W2047967234 @default.
- W1857358013 hasRelatedWork W2118496982 @default.
- W1857358013 hasRelatedWork W2364998975 @default.
- W1857358013 hasRelatedWork W2369162477 @default.
- W1857358013 hasRelatedWork W2439875401 @default.
- W1857358013 hasRelatedWork W2994319618 @default.
- W1857358013 hasRelatedWork W4238867864 @default.
- W1857358013 hasRelatedWork W2525756941 @default.
- W1857358013 hasVolume "12" @default.
- W1857358013 isParatext "false" @default.
- W1857358013 isRetracted "false" @default.
- W1857358013 magId "1857358013" @default.
- W1857358013 workType "article" @default.